Christine Camacho-Bydume

Christine Camacho-Bydume

Auto-generated profile, based on publicly available information

Christine Camacho-Bydume

Department of Pediatric Hematology/Oncology Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center Hackensack New Jersey USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
JSJennifer N Saultz
Jennifer N Saultz
YBYung-Tsi Bolon
Yung-Tsi Bolon
TWTao Wang
Tao Wang
SSStephen R. Spellman
Stephen R. Spellman
SLStephanie Lee
Stephanie Lee
EAEsteban Arrieta-Bolaños
Esteban Arrieta-Bolaños

19 June 2026 in European Journal of Haematology
Verified
Journal Article
Open access
GGGregory M.T. Guilcher
Gregory M.T. Guilcher
AAAllistair Abraham
Allistair Abraham
SAStaci D. Arnold
Staci D. Arnold
CCChristine Camacho‐Bydume
Christine Camacho‐Bydume
JDJenny Duong
Jenny Duong
ESElizabeth O. Stenger
Elizabeth O. Stenger
Background: Sickle cell disease (SCD) is a chronic and life‐limiting hemoglobin and systemic vascular disease. While over 1000 people have undergone hematopoietic cell transplantation (HCT) over the last 40 years, long‐term disease‐specific and health‐related quality of life data are lacking. The American Society of Hematology 2021 Guidelines for SCD emphasized the need for more detailed registry data to inform patients and providers with decision‐making and practice recommendations. Procedures: In January 2021, the Sickle Cell Transplant Advocacy and Research Alliance (STAR) launched Project Sickle Cure (PSC). This multi‐center, prospective study of patients who have undergone HCT for SCD includes baseline demographics and SCD‐specific post‐HCT outcomes, serial neurocognitive testing, health‐related quality of life measures, health equity evaluations, a neuroimaging bank, detailed evaluation of neurologic status pre‐ and post‐transplant, and chronic pain evaluation. A biorepository is in the planning stage of development. Results: As of November 2025, 115 participants have enrolled at 18 STAR sites with enrollment ongoing. Conclusions: PSC is a STAR prospective study which will address a major gap in our understanding of outcomes post‐HCT specific to SCD. WeDecide, a larger study comparing HCT health‐related quality of life outcomes to those who receive non‐transplant disease modifying therapy (NT‐DMT) is in development, and PSC will provide the HCT comparator data. These data will also be highly relevant as other curative and transformative therapies, such as gene therapy, become more widely used.